CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 87.41% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Scan to Download iOS&Android APP

Trade Maravai Life Sciences Inc. - MRVI CFD

12.38
5.96%
0.18
Low: 12.21
High: 13.08
Market Trading Hours* (UTC) Opens on Wednesday at 14:30

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.18
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.0308 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.0308%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.0308 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.0137%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 13.26
Open* 13.08
1-Year Change* -68.91%
Day's Range* 12.21 - 12.21
52 wk Range 13.405-46.29
Average Volume (10 days) 2.67412
Average Volume (3 months) 44.3719
Market Cap 3662.25
P/E Ratio 6.11174
Shares Outstanding 255209000
Revenue 906.732
EPS 2.34794
Dividend (Yield %) N/A
Beta N/A
Next Earnings Date Feb 21, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 5, 2022 13.26 -0.52 -3.77% 13.78 13.81 12.96
Dec 2, 2022 13.80 -0.52 -3.63% 14.32 14.32 13.59
Dec 1, 2022 14.30 -0.46 -3.12% 14.76 14.83 14.25
Nov 30, 2022 14.82 0.93 6.70% 13.89 14.83 13.89
Nov 29, 2022 14.13 -0.08 -0.56% 14.21 14.49 14.00
Nov 28, 2022 14.33 0.28 1.99% 14.05 14.53 13.97
Nov 25, 2022 14.24 0.20 1.42% 14.04 14.31 13.92
Nov 23, 2022 14.22 0.51 3.72% 13.71 14.48 13.71
Nov 22, 2022 14.30 0.70 5.15% 13.60 14.39 13.60
Nov 21, 2022 14.10 -0.12 -0.84% 14.22 14.51 13.89
Nov 18, 2022 14.42 0.06 0.42% 14.36 14.79 14.35
Nov 17, 2022 14.35 0.51 3.68% 13.84 14.39 13.61
Nov 16, 2022 14.31 -0.36 -2.45% 14.67 14.89 14.10
Nov 15, 2022 14.94 -0.30 -1.97% 15.24 15.52 14.66
Nov 14, 2022 14.90 -0.06 -0.40% 14.96 15.77 14.84
Nov 11, 2022 15.68 1.36 9.50% 14.32 16.02 14.31
Nov 10, 2022 14.68 0.63 4.48% 14.05 14.83 13.76
Nov 9, 2022 13.43 -0.55 -3.93% 13.98 14.20 13.36
Nov 8, 2022 14.22 0.07 0.49% 14.15 14.86 13.97
Nov 7, 2022 14.12 -1.37 -8.84% 15.49 15.55 13.98

Maravai Life Sciences Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2018 2019 2020 2021
Total revenue 123.833 143.14 284.098 799.24
Revenue 123.833 143.14 284.098 799.24
Cost of Revenue, Total 60.765 66.849 79.649 140.561
Gross Profit 63.068 76.291 204.449 658.679
Total Operating Expense 113.019 119.152 171.788 244.595
Selling/General/Admin. Expenses, Total 33.194 40.354 94.245 100.064
Research & Development 4.499 3.627 1.704 9.319
Depreciation / Amortization 8 8 7.6 5.9
Unusual Expense (Income) 5.622 0 -11.41 -11.249
Other Operating Expenses, Total 0.939 0.322 0 0
Operating Income 10.814 23.988 112.31 554.645
Interest Income (Expense), Net Non-Operating -27.399 -29.959 -30.74 -30.26
Other, Net 0.087 0.118 0.126 6.38
Net Income Before Taxes -16.498 -5.853 81.696 530.765
Net Income After Taxes -16.915 -5.201 78.816 469.25
Minority Interest 4.446 2.4 13.342 -287.213
Net Income Before Extra. Items -12.469 -2.801 92.158 182.037
Net Income -12.469 -2.801 92.158 182.037
Total Adjustments to Net Income -5.259 -5.68 -15.27
Income Available to Common Excl. Extra. Items -17.728 -8.481 76.888 182.037
Income Available to Common Incl. Extra. Items -17.728 -8.481 76.888 182.037
Diluted Net Income -17.728 -8.481 76.888 402.356
Diluted Weighted Average Shares 257.621 257.621 257.621 257.803
Diluted EPS Excluding Extraordinary Items -0.06881 -0.03292 0.29845 1.56071
Dividends per Share - Common Stock Primary Issue 0 0
Diluted Normalized EPS -0.05463 -0.03292 0.27165 1.52746
Dilution Adjustment 220.319
Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022
Total revenue 148.211 217.775 204.81 228.444 244.293
Revenue 148.211 217.775 204.81 228.444 244.293
Cost of Revenue, Total 31.391 37.513 32.047 40.633 40.032
Gross Profit 116.82 180.262 172.763 187.811 204.261
Total Operating Expense 57.022 63.53 47.937 77.359 77.135
Selling/General/Admin. Expenses, Total 21.571 24.085 25.189 27.553 32.4
Research & Development 2.16 0.032 0.45 8.573 3.695
Depreciation / Amortization 1.9 1.9 1.5 0.6 0.8
Unusual Expense (Income) 0 0 -11.249 0 0.208
Operating Income 91.189 154.245 156.873 151.085 167.158
Interest Income (Expense), Net Non-Operating -7.904 -8.512 -8.545 -4.433 -2.664
Other, Net 5.889 -0.003 3.324 -2.83 2.347
Net Income Before Taxes 89.174 145.73 151.652 143.822 166.841
Net Income After Taxes 75.465 134.344 132.81 126.244 146.86
Minority Interest -52.363 -85.269 -78.536 -70.803 -79.998
Net Income Before Extra. Items 23.102 49.075 54.274 55.441 66.862
Net Income 23.102 49.075 54.274 55.441 66.862
Income Available to Common Excl. Extra. Items 23.102 49.075 54.274 55.441 66.862
Income Available to Common Incl. Extra. Items 23.102 49.075 54.274 55.441 66.862
Diluted Net Income 23.102 49.094 115.148 109.642 127.963
Diluted Weighted Average Shares 96.673 112.28 258.028 257.815 255.287
Diluted EPS Excluding Extraordinary Items 0.23897 0.43724 0.44626 0.42527 0.50125
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS 0.24698 0.44554 0.40691 0.42793 0.48959
Total Adjustments to Net Income 0 0
Dilution Adjustment 0.019 60.874 54.201 61.101
Other Operating Expenses, Total 0
  • Annual
  • Quarterly
2018 2019 2020 2021
Total Current Assets 53.802 60.552 331.598 740.039
Cash and Short Term Investments 21.866 24.7 236.184 551.272
Cash 21.866 24.7 236.184 551.272
Total Receivables, Net 15.991 18.83 51.218 117.512
Accounts Receivable - Trade, Net 15.991 18.83 51.218 117.512
Total Inventory 14.308 14.202 33.301 51.557
Prepaid Expenses 1.637 2.82 10.895 19.698
Total Assets 539.676 577.796 1270.69 1918.28
Property/Plant/Equipment, Total - Net 42.578 94.311 101.305 95.427
Property/Plant/Equipment, Total - Gross 31.492 102.41 111.952 107.959
Accumulated Depreciation, Total -4.289 -8.099 -10.647 -12.532
Goodwill, Net 224.275 224.275 224.275 152.766
Intangibles, Net 218.127 197.853 177.656 117.571
Other Long Term Assets, Total 0.894 0.805 435.857 812.473
Total Current Liabilities 35.919 29.562 130.778 93.777
Accounts Payable 3.604 7.478 8.171 8.154
Accrued Expenses 11.147 16.515 29.014 29.34
Notes Payable/Short Term Debt 0 0 0 0
Current Port. of LT Debt/Capital Leases 2.5 2.5 6 6
Other Current Liabilities, Total 18.668 3.069 87.593 50.283
Total Liabilities 395.271 436.4 1182.18 1602.78
Total Long Term Debt 337.389 387.702 584.781 524.591
Long Term Debt 335.55 334.783 528.614 524.591
Capital Lease Obligations 1.839 52.919 56.167 0
Deferred Income Tax 15.856 14.697 8.609 0
Minority Interest 3.611 3.231 66.235 229.862
Other Liabilities, Total 2.496 1.208 391.777 754.547
Total Equity 144.405 141.396 88.511 315.499
Common Stock 182.809 183.91 2.576 2.552
Retained Earnings (Accumulated Deficit) -38.237 -42.381 0.854 184.561
Other Equity, Total -0.167 -0.133 -0.044 0
Total Liabilities & Shareholders’ Equity 539.676 577.796 1270.69 1918.28
Total Common Shares Outstanding 257.621 257.621 257.621 255.157
Additional Paid-In Capital 85.125 128.386
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 425.543 644.491 687.478 740.039 619.135
Cash and Short Term Investments 247.675 374.71 547.898 551.272 431.469
Cash 247.675 374.71 547.898 551.272 431.469
Total Receivables, Net 122.821 83.534 65.939 117.512 120.355
Accounts Receivable - Trade, Net 122.821 83.534 65.939 117.512 120.355
Total Inventory 47.129 47.781 56.246 51.557 51.409
Prepaid Expenses 7.918 13.432 17.395 19.698 15.902
Total Assets 1351.77 1601.25 1894.68 1918.28 2043.23
Property/Plant/Equipment, Total - Net 105.133 104.751 108.322 46.332 47.702
Goodwill, Net 224.275 152.766 152.766 152.766 283.535
Intangibles, Net 172.616 125.116 121.225 117.571 235.405
Other Long Term Assets, Total 424.201 574.123 824.892 861.568 857.453
Total Current Liabilities 165.252 164.773 114.352 93.777 86.675
Accounts Payable 9.806 11.704 8.917 8.154 10.384
Accrued Expenses 28.973 17.711 30.248 29.34 32.411
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 6 7.083 7.174 6 5.44
Other Current Liabilities, Total 120.473 128.275 68.013 50.283 38.44
Total Liabilities 1239.16 1407.33 1592.05 1602.78 1660.67
Total Long Term Debt 583.517 582.209 580.908 524.591 524.499
Long Term Debt 527.593 526.583 525.584 524.591 524.499
Capital Lease Obligations 55.924 55.626 55.324 0
Deferred Income Tax 8.571 0 0 0
Minority Interest 97.145 139.22 150.979 229.862 271.743
Other Liabilities, Total 384.672 521.124 745.807 754.547 777.754
Total Equity 112.611 193.921 302.637 315.499 382.559
Common Stock 2.576 2.576 2.576 2.552 2.552
Additional Paid-In Capital 85.976 118.208 172.611 128.386 128.584
Retained Earnings (Accumulated Deficit) 24.101 73.176 127.45 184.561 251.423
Other Equity, Total -0.042 -0.039 0 0
Total Liabilities & Shareholders’ Equity 1351.77 1601.25 1894.68 1918.28 2043.23
Total Common Shares Outstanding 257.621 257.66 257.66 255.157 255.159
Other Current Assets, Total 125.034
  • Annual
  • Quarterly
2018 2019 2020 2021
Net income/Starting Line -16.915 -5.201 78.816 469.25
Cash From Operating Activities -0.186 24.115 152.187 368.57
Cash From Operating Activities 2.225 3.81 5.517 6.413
Amortization 20.122 20.274 20.32 18.339
Deferred Taxes 0.317 -1.159 -5.464 46.904
Non-Cash Items 9.906 4.101 17.105 4.295
Cash Taxes Paid -0.097 -0.802 5.006 22.473
Cash Interest Paid 25.678 28.728 28.916 27.234
Changes in Working Capital -15.841 2.29 35.893 -176.631
Cash From Investing Activities -3.451 -17.148 6.068 105.655
Capital Expenditures -3.611 -17.148 -28.432 -14.85
Other Investing Cash Flow Items, Total 0.16 0 34.5 120.505
Cash From Financing Activities -9.167 -4.167 53.212 -159.049
Financing Cash Flow Items -64.595 -1.527 -444.983 -154.758
Issuance (Retirement) of Debt, Net 55.428 -2.64 196.924 -6
Foreign Exchange Effects -0.069 0.034 0.017 -0.088
Net Change in Cash -12.873 2.834 211.484 315.088
Issuance (Retirement) of Stock, Net 301.271 1.709
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line 75.465 210.196 343.006 469.25 146.86
Cash From Operating Activities 38.326 204.297 310.403 368.57 162.304
Cash From Operating Activities 1.256 4.151 6.623 6.413 1.855
Amortization 5.041 10.081 14.685 18.339 5.527
Deferred Taxes 11.76 18.211 29.438 46.904 13.217
Non-Cash Items -0.876 -0.133 -11.033 4.295 3.083
Cash Taxes Paid 2.725 9.087 -16.569 22.473 0.914
Cash Interest Paid 7.219 15.547 23.03 27.234 1.373
Changes in Working Capital -54.32 -38.209 -72.316 -176.631 -8.238
Cash From Investing Activities -2.784 -7.234 111.317 105.655 -241.584
Capital Expenditures -3.332 -7.782 -9.188 -14.85 -241.584
Other Investing Cash Flow Items, Total 0.548 0.548 120.505 120.505 0
Cash From Financing Activities -24.058 -58.55 -110.051 -159.049 -40.523
Financing Cash Flow Items -23.128 -56.203 -106.298 -154.758 -39.889
Issuance (Retirement) of Stock, Net 0.57 1.018 1.329 1.709 0.726
Issuance (Retirement) of Debt, Net -1.5 -3.365 -5.082 -6 -1.36
Foreign Exchange Effects 0.007 0.013 0.045 -0.088 0
Net Change in Cash 11.491 138.526 311.714 315.088 -119.803
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
GTCR Golder Rauner, LLC Private Equity 16.4825 21681033 0 2022-09-30 LOW
MFS Investment Management Investment Advisor/Hedge Fund 10.5967 13938892 1459685 2022-09-30 LOW
Select Equity Group, L.P. Investment Advisor/Hedge Fund 8.759 11521575 -4929263 2022-10-31 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 7.7487 10192617 -220435 2022-09-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 3.8298 5037672 -45681 2022-09-30 LOW
Ownership Capital Investment Advisor 3.1088 4089326 -302724 2022-09-30 LOW
American Century Investment Management, Inc. Investment Advisor/Hedge Fund 2.9636 3898351 1501611 2022-09-30 LOW
ClearBridge Investments, LLC Investment Advisor/Hedge Fund 2.2622 2975735 267860 2022-09-30 LOW
JP Morgan Asset Management Investment Advisor 2.2546 2965668 68095 2022-09-30 LOW
Thrivent Asset Management, LLC Investment Advisor 1.946 2559746 2559746 2022-09-30 LOW
Fidelity Management & Research Company LLC Investment Advisor 1.9182 2523185 -1037590 2022-09-30 LOW
Artemis Investment Management LLP Investment Advisor/Hedge Fund 1.8829 2476728 242162 2022-09-30 LOW
Marshall Wace LLP Investment Advisor/Hedge Fund 1.579 2077036 1538680 2022-09-30 HIGH
Citi Investment Research (US) Research Firm 1.4941 1965345 517954 2022-09-30 LOW
Citadel Advisors LLC Hedge Fund 1.3868 1824165 1687956 2022-09-30 HIGH
Millennium Management LLC Hedge Fund 1.3656 1796274 1687021 2022-09-30 HIGH
State Street Global Advisors (US) Investment Advisor/Hedge Fund 1.3342 1754976 6088 2022-09-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.2681 1668086 38486 2022-09-30 LOW
Alyeska Investment Group, L.P. Hedge Fund 1.2236 1609572 586041 2022-09-30 HIGH
Renaissance Technologies LLC Hedge Fund 1.1576 1522700 -352300 2022-09-30 HIGH

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
475000+

Traders

71000+

Active clients monthly

$51000000+

Monthly investing volume

$30000000+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

Maravai Life Sciences Inc. Company profile

Maravai Life Sciences Inc. provides in vitro diagnostic products, diagnostic laboratory services, and life sciences tools. The company was founded in 2014 and is based in San Diego, California.
Industry: Bio Therapeutic Drugs

10770 Wateridge Circle Suite 200
Suite 200
SAN DIEGO
CALIFORNIA 92121
US

Income Statement

People also watch

US100

11,519.80 Price
-2.190% 1D Chg, %
Long position overnight fee -0.0170%
Short position overnight fee 0.0061%
Overnight fee time 22:00 (UTC)
Spread 1.8

Natural Gas

5.36 Price
-4.090% 1D Chg, %
Long position overnight fee 0.0407%
Short position overnight fee -0.0655%
Overnight fee time 22:00 (UTC)
Spread 0.005

BTC/USD

17,005.60 Price
-0.030% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 60.00

Oil - Crude

74.43 Price
-3.990% 1D Chg, %
Long position overnight fee -0.0095%
Short position overnight fee -0.0056%
Overnight fee time 22:00 (UTC)
Spread 0.03

Still looking for a broker you can trust?

Join the 475.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading